亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AAPG 亚盛医药

盘后交易 07-18 16:04:12 EDT

40.39

+0.77

+1.94%

盘后40.39

+0.000.00%

16:00 EDT

最高41.38	最低40.00	成交量6,807
今开40.00	昨收39.62	日振幅3.47%
总市值34.66亿	流通市值3.34亿	总股本8,582万
成交额27.73万	换手率0.08%	流通股本826.01万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AAPG","market":"US","secType":"STK","nameCN":"亚盛医药","latestPrice":40.39,"timestamp":1752868800000,"preClose":39.6201,"halted":0,"volume":6807,"hourTrading":{"tag":"盘后","latestPrice":40.39,"preClose":40.39,"latestTime":"16:00 EDT","volume":98,"amount":3958.2200000000003,"timestamp":1752868801350},"delay":0,"floatShares":8260100,"shares":85818665,"eps":-0.735552,"marketStatus":"盘后交易","change":0.7699,"latestTime":"07-18 16:04:12 EDT","open":40.0037,"high":41.38,"low":40.0037,"amount":277348.96869,"amplitude":0.034737,"askPrice":41.2,"askSize":1,"bidPrice":40.19,"bidSize":110,"shortable":3,"etf":0,"ttmEps":-0.735552,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1752883200000},"marketStatusCode":4,"adr":0,"adrRate":4,"listingDate":1737694800000,"exchange":"NASDAQ","adjPreClose":39.6201,"postHourTrading":{"tag":"盘后","latestPrice":40.39,"preClose":40.39,"latestTime":"16:00 EDT","volume":98,"amount":3958.2200000000003,"timestamp":1752868801350},"volumeRatio":0.626415},"requestUrl":"/m/hq/s/AAPG","defaultTab":"news","newsList":[{"id":"2552545501","title":"亚盛医药啃下“硬骨头”，百亿Bcl-2药物市场格局生变","url":"https://stock-news.laohu8.com/highlight/detail?id=2552545501","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552545501?lang=zh_cn&edition=full","pubTime":"2025-07-18 10:45","pubTimestamp":1752806700,"startTime":"0","endTime":"0","summary":"一款中国原创药物，打破了跨国药企近十年的垄断，彻底改写了全球抗癌药市场的竞争格局。近日，创新药企亚盛医药（纳斯达克代码：AAPG；香港联交所代码：6855）宣布，公司自主研发的新型Bcl-2选择性抑制剂利生妥?（通用名：利沙托克拉；研发代码：APG-2575）获中国国家药品监督管理局（NMPA）批准附条件上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507183460886641.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507183460886641.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2552458739","title":"亚盛医药7月17日成交额为22.96万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2552458739","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552458739?lang=zh_cn&edition=full","pubTime":"2025-07-18 09:15","pubTimestamp":1752801314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月17日，亚盛医药成交额为22.96万美元，成交额较昨日减少51.43%，当日成交量为5812.00股。亚盛医药于2025年7月17日涨2.59%，报39.62美元，该股过去5个交易日跌2.75%，年初至今涨129.68%，过去60日涨107.22%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091528a452215d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250718091528a452215d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2552688105","title":"首个国产原研！亚盛医药创新抗癌药国内获批上市，影响有多大？","url":"https://stock-news.laohu8.com/highlight/detail?id=2552688105","media":"澎湃新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552688105?lang=zh_cn&edition=full","pubTime":"2025-07-17 14:02","pubTimestamp":1752732157,"startTime":"0","endTime":"0","summary":"Bcl-2抑制剂可特异性地结合并抑制Bcl-2蛋白，有效恢复肿瘤细胞的凋亡通路，诱导癌细胞死亡。此次中国原创、全球创新的药物有望改写全球Bcl-2抑制剂市场的竞争格局。利沙托克拉是亚盛医药第二个获批上市、进入商业化阶段的原创新药，未来是否也会考虑BD？亚盛医药目前已经有两款产品获批，“我们希望2027年做到收支平衡有利润”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071714035797a95af1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","06855"],"gpt_icon":0},{"id":"2552725281","title":"亚盛医药再涨超7%近期配股净筹超14.9亿港元利沙托克拉新药上市申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2552725281","media":"动脉网","labels":["shareholding","productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552725281?lang=zh_cn&edition=full","pubTime":"2025-07-17 10:06","pubTimestamp":1752717960,"startTime":"0","endTime":"0","summary":"亚盛医药-B股价涨超7%，配股筹14.93亿港元，新药利沙托克拉上市填补国内空白，全球商业化潜力大，有望成第二款获批的BCL-2抑制剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710152197a92516&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071710152197a92516&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG","ASPHF"],"gpt_icon":0},{"id":"1110572086","title":"港股创新药概念股午后持续走高！丽珠医药涨超13%，复星医药涨超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1110572086","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110572086?lang=zh_cn&edition=full","pubTime":"2025-07-16 13:39","pubTimestamp":1752644353,"startTime":"0","endTime":"0","summary":"7月16日，港股创新药概念股午后持续走高，$丽珠医药(01513)$涨超13%，$复星医药(02196)$涨超8%，$绿叶制药(02186)$涨超7%，$康方生物(09926)$涨近6%，$东阳光长江药业(01558)$、$亚盛医药-B(06855)$涨超4%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4e7834c15c47c74e9bfd4d734ca81974","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07226","09926","02196","AAPG","BK1606","LU0417516571.SGD","01558","BK1574","HSTECH","BK4139","01513","YANG","06978","LU1720050803.USD","HSCEI","02186","IE00B543WZ88.USD","BK1515","IE00B5MMRT66.SGD","BK4614"],"gpt_icon":0},{"id":"2551111185","title":"港股异动 | 亚盛医药(06855)午前涨超4% 公司配股净筹近15亿港元 加速商业化及创新药研发","url":"https://stock-news.laohu8.com/highlight/detail?id=2551111185","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551111185?lang=zh_cn&edition=full","pubTime":"2025-07-16 11:54","pubTimestamp":1752638052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，亚盛医药午前涨超4%，截至发稿，涨4.11%，报74.75港元，成交额4.95亿港元。消息面上，亚盛医药近日宣布，拟按每股68.60港元的价格发行最多2200万股新股，配售事项所得净额约为14.93亿港元。董事认为，配售事项及认购事项将进一步巩固本集团的财务状况，并为本集团提供额外营运资金。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"4e7834c15c47c74e9bfd4d734ca81974","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1318372.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","06978","BK1574","AAPG","BK4139","159992","06855"],"gpt_icon":0},{"id":"2551113161","title":"亚盛医药7月15日成交额为46.82万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551113161","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551113161?lang=zh_cn&edition=full","pubTime":"2025-07-16 09:15","pubTimestamp":1752628515,"startTime":"0","endTime":"0","summary":"美东时间2025年7月15日，亚盛医药成交额为46.82万美元，成交额较昨日减少25.17%，当日成交量为1.26万股。亚盛医药于2025年7月15日涨1.55%，报36.76美元，该股过去5个交易日跌11.1%，年初至今涨113.1%，过去60日涨94.81%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-15|46.82万|-25.17%|1.26万|#|2025-07-14|62.56万|157.41%|1.72万|#|2025-07-11|24.30万|-66.18%|6315.00|#|2025-07-10|71.87万|240.51%|1.75万|#|2025-07-09|21.11万|-57.18%|5040.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091531a44d6980&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250716091531a44d6980&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2551132119","title":"越疆折价配股合共净筹约25亿港元 盘初股价均走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2551132119","media":"金吾资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551132119?lang=zh_cn&edition=full","pubTime":"2025-07-15 09:48","pubTimestamp":1752544097,"startTime":"0","endTime":"0","summary":"金吾财讯 | 越疆 及亚盛医药均折价配股抽水，合共净筹约25亿港元，盘初股价均走低。截至发稿，越疆报58.3港元，跌2.83%，成交额5718.93万港元；亚盛医药报71.7港元，跌4.02%，成交额19.13亿港元。公司有90日禁售承诺。亚盛医药宣布，拟先旧后新配售最多2200万股新股份，占扩大后的已发行股本约5.92%，每股配售价为68.6港元，较上交易日收市价74.7港元折让约8.17%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025071509485097a65f98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139","06855"],"gpt_icon":0},{"id":"2551188991","title":"亚盛医药拟配股筹资最多15.4亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2551188991","media":"DoNews","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551188991?lang=zh_cn&edition=full","pubTime":"2025-07-14 19:13","pubTimestamp":1752491583,"startTime":"0","endTime":"0","summary":"2025年7月14日，交易文件显示，亚盛医药计划通过先旧后新方式配售股份，预计筹资至多15.4亿港元（约1.96亿美元）。公司拟配售2,200万股股份，每股配售价在68.35至70港元之间，较上周一收盘价74.70港元折让6.3%-8.5%。此次配股旨在增强公司资金流动性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714191420954206e8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ASPHF","AAPG","06855","BK4139"],"gpt_icon":0},{"id":"2551920501","title":"中金：升亚盛医药-B(06855)目标价至88港元 评级“跑赢行业”","url":"https://stock-news.laohu8.com/highlight/detail?id=2551920501","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551920501?lang=zh_cn&edition=full","pubTime":"2025-07-14 10:04","pubTimestamp":1752458674,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，考虑到利生妥获批上市及全球适应症拓展前景，维持亚盛医药-B跑赢行业评级，根据DCF模型，上调目标价27.5%至88港币，较当前股价有15.3%的上行空间。根据公司公告，此前，中国尚未有Bcl-2抑制剂获批用于治疗CLL/SLL，全球也仅艾伯维的维奈克拉获批上市。该行认为利生妥的获批上市有望为国内CLL/SLL后线患者带来新的治疗选择，建议关注后续商业化为公司业绩带来的增量。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1317167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","06855"],"gpt_icon":0},{"id":"2551927949","title":"亚盛医药利刃出鞘","url":"https://stock-news.laohu8.com/highlight/detail?id=2551927949","media":"药智网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2551927949?lang=zh_cn&edition=full","pubTime":"2025-07-14 09:43","pubTimestamp":1752457417,"startTime":"0","endTime":"0","summary":"近日，根据NMPA官网的消息，亚盛医药万众期待的管线利沙托克拉片已附条件批准上市，用于既往经过至少包含布鲁顿酪氨酸激酶抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者。利刃出鞘维奈克拉上市之后，近十年之久无后来者，而直到如今，第二款药物——利沙托克拉片才获批上市。亚盛医药的后备军作为一家目前市值已经较高的biotech，亚盛医药肯定不止奥雷巴替尼和APG-2575两个大单品支撑，后面肯定还有生力军。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250714094538a6a78424&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK1161","ASPHF","06855","BK1574"],"gpt_icon":0},{"id":"2550998338","title":"亚盛医药7月11日成交额为24.30万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550998338","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550998338?lang=zh_cn&edition=full","pubTime":"2025-07-12 09:15","pubTimestamp":1752282914,"startTime":"0","endTime":"0","summary":"美东时间2025年7月11日，亚盛医药成交额为24.30万美元，成交额较昨日减少66.18%，当日成交量为6315.00股。亚盛医药于2025年7月11日跌6.14%，报38.24美元，该股过去5个交易日跌10.76%，年初至今涨121.68%，过去60日涨86.63%。公司专注于开发抑制蛋白质相互作用以恢复细胞凋亡或程序性细胞死亡的疗法。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091523a445c7f1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250712091523a445c7f1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2550098026","title":"亚盛医药拿下全球第二个Bcl-2抑制剂 在国内与“全球首个”前后脚获批血液肿瘤适应证","url":"https://stock-news.laohu8.com/highlight/detail?id=2550098026","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550098026?lang=zh_cn&edition=full","pubTime":"2025-07-11 16:39","pubTimestamp":1752223174,"startTime":"0","endTime":"0","summary":"全球第二个Bcl-2抑制剂，来自中国。7月10日，亚盛医药发布公告，公司自研的新型Bcl-2选择性抑制剂“利生妥”（通用名：利沙托克拉）获附条件批准，可用于既往经过至少包含布鲁顿酪氨酸激酶（BTK）抑制剂在内的一种系统治疗的成人慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL/SLL）患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202507113454576954.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202507113454576954.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2550617943","title":"亚盛医药：新药利沙托克拉获中国NMPA附条件批准上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550617943","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550617943?lang=zh_cn&edition=full","pubTime":"2025-07-10 17:01","pubTimestamp":1752138081,"startTime":"0","endTime":"0","summary":"亚盛医药公告要点解读核心事件新药获批上市：公司自主研发的新型Bcl-2抑制剂利沙托克拉（利生妥）获中国NMPA附条件批准上市，成为中国首个上市用于治疗CLL/SLL的Bcl-2抑制剂，全球第二个上市的同类药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710170428a6a13e17&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0},{"id":"2550314611","title":"国产首个！亚盛医药Bcl-2抑制剂“利沙托克拉”获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2550314611","media":"医药魔方Info","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550314611?lang=zh_cn&edition=full","pubTime":"2025-07-10 15:43","pubTimestamp":1752133404,"startTime":"0","endTime":"0","summary":"APG-2575是亚盛医药自主研发的新型口服Bcl-2选择性抑制剂，通过选择性抑制Bcl-2蛋白，恢复癌细胞的正常凋亡过程，从而达到治疗肿瘤的目的。Bcl-2抑制剂的出现让CLL/SLL的治疗有了进一步的革新。不过Bcl-2靶点成药性难度很高，靶点发现至今近40年，全球只有一款靶向Bcl-2的抑制剂获批上市，即艾伯维维奈克拉，此外，百济神州的索托克拉已申请上市，目前正在审评当中。力胜克拉的获批将为患者提供新的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710155605a44207f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","ASPHF","06855","AAPG","BK1161"],"gpt_icon":0},{"id":"2550966716","title":"亚盛医药7月9日成交额为21.11万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550966716","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550966716?lang=zh_cn&edition=full","pubTime":"2025-07-10 09:15","pubTimestamp":1752110115,"startTime":"0","endTime":"0","summary":"美东时间2025年7月9日，亚盛医药成交额为21.11万美元，成交额较昨日减少57.18%，当日成交量为5040.00股。亚盛医药于2025年7月9日涨1.26%，报41.87美元，该股过去5个交易日涨7.39%，年初至今涨142.72%，过去60日涨136.55%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-09|21.11万|-57.18%|5040.00|#|2025-07-08|49.29万|93.32%|1.19万|#|2025-07-07|25.50万|-73.46%|6072.00|#|2025-07-03|96.08万|334.10%|2.25万|#|2025-07-02|22.13万|1.03%|5607.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091529a6a0632a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250710091529a6a0632a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2549596497","title":"亚盛医药（06855）任命Veet Misra博士为首席财务官 任命黄智为全球企业发展&财务高级副总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2549596497","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549596497?lang=zh_cn&edition=full","pubTime":"2025-07-08 11:51","pubTimestamp":1751946699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，7月8日，亚盛医药宣布，公司任命Veet Misra博士为首席财务官，并任命黄智先生为全球企业发展&财务高级副总裁。Misra博士和黄智先生均向公司董事长兼首席执行官杨大俊博士直接汇报。亚盛医药作为港股、纳斯达克双重主要上市的全球性创新药企业，正迈向新的历史发展阶段。亚盛医药首席财务官Veet Misra博士指出，加入亚盛医药担任首席财务官，我深感振奋。Misra博士拥有20多年的投资银行从业经验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1315021.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1161","BK4139","06855","BK1574"],"gpt_icon":0},{"id":"2549628415","title":"亚盛医药7月7日成交额为25.50万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2549628415","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549628415?lang=zh_cn&edition=full","pubTime":"2025-07-08 09:15","pubTimestamp":1751937314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月7日，亚盛医药成交额为25.50万美元，成交额较昨日减少73.46%，当日成交量为6072.00股。亚盛医药于2025年7月7日跌1.89%，报42.04美元，该股过去5个交易日涨6.16%，年初至今涨143.71%，过去60日涨116.03%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-07|25.50万|-73.46%|6072.00|#|2025-07-03|96.08万|334.10%|2.25万|#|2025-07-02|22.13万|1.03%|5607.00|#|2025-07-01|21.91万|-18.59%|5597.00|#|2025-06-30|26.91万|1.80%|6844.00|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091524a69bea2a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708091524a69bea2a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","AAPG"],"gpt_icon":0},{"id":"2548236822","title":"【港股生物医药板块震荡走强】港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2548236822","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548236822?lang=zh_cn&edition=full","pubTime":"2025-07-03 14:05","pubTimestamp":1751522751,"startTime":"0","endTime":"0","summary":"港股生物医药板块震荡走强，康方生物、圣诺医药、歌礼制药涨超10%，亚盛医药涨超7%，复宏汉霖、科技药业、再鼎医药涨超4%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/07/03140551458806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","AAPG","BK1191","BK4585","BK4588","02257","09688","ZLAB","399441","BK4531","YANG","09926","BK4526","BK1161","HSCEI","07226","01477","BK4139","LU0348784397.USD","LU0348783233.USD","LU1720050803.USD","BK4548","01672","IE00B543WZ88.USD","HSTECH","LU2488822045.USD","LU0417516571.SGD","BK1588","BK4614","IE00B5MMRT66.SGD","BK1515","LU1794554557.SGD","02696","161726","IE00BPRC5H50.USD"],"gpt_icon":0},{"id":"2548888842","title":"亚盛医药7月2日成交额为22.13万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548888842","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548888842?lang=zh_cn&edition=full","pubTime":"2025-07-03 09:15","pubTimestamp":1751505314,"startTime":"0","endTime":"0","summary":"美东时间2025年7月2日，亚盛医药成交额为22.13万美元，成交额较昨日增加1.03%，当日成交量为5607.00股。亚盛医药于2025年7月2日涨2.21%，报39.85美元，该股过去5个交易日跌0.35%，年初至今涨131.01%，过去60日涨90.21%。|近5个交易日成交情况||||#|日期|成交额（美元）|成交额较昨日变化|成交量（股）|#|2025-07-02|22.13万|1.03%|5607.00|#|2025-07-01|21.91万|-18.59%|5597.00|#|2025-06-30|26.91万|1.80%|6844.00|#|2025-06-27|26.43万|-53.92%|6734.00|#|2025-06-26|57.36万|-24.94%|1.45万|亚盛医药集团是一家临床阶段的生物技术公司，从事癌症、乙型肝炎病毒和某些年龄相关疾病的新型小规模疗法的开发和销售。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703091529a4cc1fa6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250703091529a4cc1fa6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["AAPG","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascentage.com","stockEarnings":[{"period":"1week","weight":-0.0275},{"period":"1month","weight":0.2522},{"period":"3month","weight":1.1165},{"period":"6month","weight":1.2968},{"period":"ytd","weight":1.2968}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":0.0511},{"period":"3month","weight":0.1931},{"period":"6month","weight":0.051},{"period":"1year","weight":0.1277},{"period":"ytd","weight":0.0716}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"亚盛医药集团成立于2017年11月17日。亚盛医药集团是一家主要从事开发癌症、乙型肝炎病毒及若干衰老相关疾病的创新微型疗法的投资控股公司。该公司拥有自主研发的蛋白-蛋白相互作用靶向药物设计平台。该公司的主要产品包括下一代激酶抑制剂HQP1351,细胞凋亡靶向药物APG-1252、APG2575、APG-115等。该公司于国内市场及美国等海外市场开展业务。","exchange":"NASDAQ","name":"亚盛医药","nameEN":"ASCENTAGE PHARMA GROUP"},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"亚盛医药,AAPG,亚盛医药股票,亚盛医药股票老虎,亚盛医药股票老虎国际,亚盛医药行情,亚盛医药股票行情,亚盛医药股价,亚盛医药股市,亚盛医药股票价格,亚盛医药股票交易,亚盛医药股票购买,亚盛医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"亚盛医药(AAPG)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供亚盛医药(AAPG)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}